Amarantus Announces Adjournment of Annual Meeting

SAN FRANCISCO and GENEVA, Aug. 3, 2015 (GLOBE NEWSWIRE) — Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan…Read More »

Amarantus BioScience, U.S. Army and Rutgers University in Partnership to Expand Development of Engineered Skin Substitute (ESS) for the Treatment of Severe Thermal Burn Wounds

SAN FRANCISCO and GENEVA, Aug. 3, 2015 (GLOBE NEWSWIRE) — Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan…Read More »

Amarantus Announces Publication of a Clinical Study of MSPrecise(R) Diagnostic for Identification of Relapsing-Remitting Multiple Sclerosis (RRMS) in the Journal GENE

- MSPrecise next generation sequencing assay supports identification of multiple sclerosis patients with 84% accuracy – – Results from this study were not combined with oligoclonal banding (OCB) –  -…Read More »

Amarantus Diagnostics Establishes Strategic Advisory Committee

Advisors Bring Over 30 Years of Expertise in Successfully Commercializing Molecular Diagnostics Companies SAN FRANCISCO and GENEVA, July 27, 2015 (GLOBE NEWSWIRE) — Amarantus Diagnostics, a neurology…Read More »

Amarantus Diagnostics Meets Primary and Secondary Endpoints in Blinded, Multi-Center LP-002 Clinical Study for LymPro(R) Blood Diagnostic for Alzheimer's Disease and Confirms LymPro's Fit-For-Purpose Use in Clinical Trials at the 2015 Alzheimer's Association International Conference(R)

LymPro discriminates Alzheimer’s disease (AD) from healthy controls with comparable accuracy to clinical diagnosis reference standard    Data corroborate previously published findings demonstrating Ly…Read More »

Forward Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements." These forward-looking statements generally are identified by the words believes," project," expects," anticipates," estimates," intends," strategy," plan," may," will," would," will be," will continue," will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

This Blog is official and sanctioned by Amarantus BioScience | See Disclaimer | See Privacy Policy

Get Amarantus BioScience Blog Post Alerts